Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Zeevat

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
The Journal of Infectious Diseases|December 22, 2021
Reply to Anglemyer et alFlorian Zeevat, Cornelis Boersma, Maarten Postma
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2022
Reducing Hospital Capacity Needs for Seasonal Respiratory Infections: The Case of Switching to High-Dose Influenza Vaccine for Dutch Older AdultsFlorian Zeevat, Jan C Wilschut, Cornelis Boersma, et al.
Vaccine|April 17, 2024
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizationsSimon van der Pol, Florian Zeevat, Maarten J Postma, et al.
Pharmacoeconomics|February 20, 2025
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant ProtectionFlorian Zeevat, Simon van der Pol, Alexia Kieffer, et al.
Vaccines|February 13, 2021
Rotavirus Vaccination of Infants Delayed and Limited within the National Immunization Programme in the Netherlands: An Opportunity LostFlorian Zeevat, Evgeni Dvortsin, Abrham Wondimu, et al.
Advances in Therapy|February 10, 2025
Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the NetherlandsFlorian Zeevat, Simon van der Pol, Tjalke Westra, et al.
Vaccine|September 28, 2025
Evaluating cost-effectiveness of RSV vaccination strategies for older adults in the NetherlandsFlorian Zeevat, Jos Luttjeboer, Koos Korsten, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 12, 2021
Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention ProgramFlorian Zeevat, Pascal Crépey, F Christiaan K Dolk, et al.
Infectious Diseases and Therapy|February 17, 2024
Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands-a Holistic ApproachFlorian Zeevat, Joost J M Simons, Tjalke A Westra, et al.
Infectious Diseases and Therapy|June 26, 2026
Cost-Effectiveness of Routine Infant Meningococcal B Vaccination in the NetherlandsJoost J M Simons, Florian Zeevat, Tjalke A Westra, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The Journal of Infectious Diseases|December 22, 2021
Reply to Anglemyer et alFlorian Zeevat, Cornelis Boersma, Maarten Postma
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2022
Reducing Hospital Capacity Needs for Seasonal Respiratory Infections: The Case of Switching to High-Dose Influenza Vaccine for Dutch Older AdultsFlorian Zeevat, Jan C Wilschut, Cornelis Boersma, et al.
Vaccine|April 17, 2024
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizationsSimon van der Pol, Florian Zeevat, Maarten J Postma, et al.
Pharmacoeconomics|February 20, 2025
Cost-Effectiveness Analysis of Nirsevimab for Preventing Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease in Dutch Infants: An Analysis Including All-Infant ProtectionFlorian Zeevat, Simon van der Pol, Alexia Kieffer, et al.
Vaccines|February 13, 2021
Rotavirus Vaccination of Infants Delayed and Limited within the National Immunization Programme in the Netherlands: An Opportunity LostFlorian Zeevat, Evgeni Dvortsin, Abrham Wondimu, et al.
Advances in Therapy|February 10, 2025
Cost-effectiveness Analysis of COVID-19 mRNA XBB.1.5 Fall 2023 Vaccination in the NetherlandsFlorian Zeevat, Simon van der Pol, Tjalke Westra, et al.
Vaccine|September 28, 2025
Evaluating cost-effectiveness of RSV vaccination strategies for older adults in the NetherlandsFlorian Zeevat, Jos Luttjeboer, Koos Korsten, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 12, 2021
Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention ProgramFlorian Zeevat, Pascal Crépey, F Christiaan K Dolk, et al.
Infectious Diseases and Therapy|February 17, 2024
Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands-a Holistic ApproachFlorian Zeevat, Joost J M Simons, Tjalke A Westra, et al.
Infectious Diseases and Therapy|June 26, 2026
Cost-Effectiveness of Routine Infant Meningococcal B Vaccination in the NetherlandsJoost J M Simons, Florian Zeevat, Tjalke A Westra, et al.
Pageof 2